Interleukin‐17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum

Hidradenitis suppurativa (HS) is an inflammatory skin disease with dysregulation of the interleukin (IL)‐17 axis. Recently, we reported the clinical benefit of brodalumab, a human anti‐IL‐17 receptor A (IL‐17RA) monoclonal antibody, in moderate‐to‐severe HS.

[1]  J. Krueger,et al.  In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. , 2021, The Journal of investigative dermatology.

[2]  C. Zouboulis,et al.  Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary. , 2021, JAMA dermatology.

[3]  G. Fabbrocini,et al.  Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  J. Krueger,et al.  Epithelialized Tunnels are a Source of Inflammation in Hidradenitis Suppurativa. , 2021, The Journal of allergy and clinical immunology.

[5]  R. Sabat,et al.  Aetiology and pathogenesis of hidradenitis suppurativa , 2020, The British journal of dermatology.

[6]  V. Piguet,et al.  A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. , 2020, The Journal of investigative dermatology.

[7]  J. Voorhees,et al.  Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis , 2020, JCI insight.

[8]  Kathleen M. Smith,et al.  Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF-α therapy , 2020, JCI insight.

[9]  J. Krueger,et al.  The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study. , 2020, Journal of the American Academy of Dermatology.

[10]  Z. Reguiaï,et al.  Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  B. Moran,et al.  IL‐17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa , 2020, Clinical and experimental immunology.

[12]  B. Strober,et al.  Hidradenitis suppurativa: Current and emerging treatments. , 2020 .

[13]  A. Gottlieb,et al.  Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial. , 2020, Journal of the American Academy of Dermatology.

[14]  J. Mac Mahon,et al.  An Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa , 2020, Patient related outcome measures.

[15]  J. Krueger,et al.  Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa , 2020, The British journal of dermatology.

[16]  K. Navrazhina,et al.  Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa , 2020, Experimental dermatology.

[17]  Caroline S. Jiang,et al.  Clinical Response Rates, Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post-Hoc Analysis of PIONEER 1 and 2 Individual Patient Data. , 2019, Journal of the American Academy of Dermatology.

[18]  J. Kirby,et al.  Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies , 2019, The British journal of dermatology.

[19]  Xiaoyu Jiang,et al.  IL-17A inhibition by secukinumab induces early clinical, histopathological, and molecular resolution of psoriasis. , 2019, The Journal of allergy and clinical immunology.

[20]  A. Gottlieb,et al.  Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa , 2019, The British journal of dermatology.

[21]  J. Krueger,et al.  Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa , 2019, Experimental dermatology.

[22]  R. Schmid,et al.  Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. , 2019, The Journal of allergy and clinical immunology.

[23]  A. Vossen,et al.  Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  M. Suárez-Fariñas,et al.  Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature , 2018, PloS one.

[25]  J. Krueger,et al.  Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis , 2018, The Journal of Immunology.

[26]  J. Krueger,et al.  Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. , 2018, The Journal of allergy and clinical immunology.

[27]  Min-jung Park,et al.  IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis , 2018, Front. Immunol..

[28]  N. Yawalkar,et al.  Increased expression of the interleukin‐36 cytokines in lesions of hidradenitis suppurativa , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[29]  B. Moran,et al.  Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. , 2017, The Journal of investigative dermatology.

[30]  H. Volk,et al.  Lipocalin‐2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa , 2017, The British journal of dermatology.

[31]  G. Fabbrocini,et al.  IL-36 cytokines are increased in acne and hidradenitis suppurativa , 2017, Archives of Dermatological Research.

[32]  E. Berti,et al.  Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis) , 2017, The British journal of dermatology.

[33]  L. Lind,et al.  Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria , 2017, European Journal of Preventive Cardiology.

[34]  S. Benzaken,et al.  Interleukin 6 and high‐sensitivity C‐reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa , 2017, Journal of the American Academy of Dermatology.

[35]  G. Kricorian,et al.  Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases. , 2016, Rheumatology.

[36]  Y. Lévy,et al.  Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. , 2016, The Journal of investigative dermatology.

[37]  A. Gottlieb,et al.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. , 2016, The New England journal of medicine.

[38]  A. Gottlieb,et al.  A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[39]  T. Cao,et al.  Increased Lipocalin-2 Contributes to the Pathogenesis of Psoriasis by Modulating Neutrophil Chemotaxis and Cytokine Secretion. , 2016, The Journal of investigative dermatology.

[40]  P. Horvatovich,et al.  Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum , 2016, The British journal of dermatology.

[41]  C. Sweeney,et al.  Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa , 2015, The British journal of dermatology.

[42]  S. Brand,et al.  Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-&agr; and Modulated by IL23R Genotype Status , 2015, Inflammatory bowel diseases.

[43]  E. Ingelsson,et al.  Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. , 2015, Atherosclerosis.

[44]  Q. Hamid,et al.  IL-17 Enhances Chemotaxis of Primary Human B Cells during Asthma , 2014, PloS one.

[45]  Hugh A. Rand,et al.  Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody , 2014, The Journal of Immunology.

[46]  S. Gaffen,et al.  Interleukin-17-Induced Protein Lipocalin 2 Is Dispensable for Immunity to Oral Candidiasis , 2013, Infection and Immunity.

[47]  G. Newton,et al.  IL-17 and TNF-α Sustain Neutrophil Recruitment during Inflammation through Synergistic Effects on Endothelial Activation , 2012, The Journal of Immunology.

[48]  J. Ortonne,et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.

[49]  J. Laman,et al.  Adalimumab (antitumour necrosis factor‐α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study , 2012, The British journal of dermatology.

[50]  Z. Modrušan,et al.  IL-17C regulates the innate immune function of epithelial cells in an autocrine manner , 2011, Nature Immunology.

[51]  K. Yuen,et al.  A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection , 2011, Cellular and Molecular Immunology.

[52]  Guangjie Chen,et al.  Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. , 2011, Immunity.

[53]  N. Yawalkar,et al.  Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. , 2011, Journal of the American Academy of Dermatology.

[54]  H. Volk,et al.  Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa , 2011, The Journal of Immunology.

[55]  J. Simon,et al.  Human fibroblasts support the expansion of IL-17-producing T cells via up-regulation of IL-23 production by dendritic cells. , 2010, Blood.

[56]  J. Szepietowski,et al.  Psychophysical aspects of hidradenitis suppurativa. , 2010, Acta dermato-venereologica.

[57]  J. Szepietowski,et al.  Hidradenitis suppurativa markedly decreases quality of life and professional activity. , 2010, Journal of the American Academy of Dermatology.

[58]  M. Washington,et al.  A Model of Chronic Bacterial Infection Dependent on Il-17 Receptor a Signaling in Regulation of Gastric B Cell Recruitment Is , 2022 .

[59]  Frann Bennett,et al.  The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex , 2008, The Journal of Immunology.

[60]  Scott R. Presnell,et al.  Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F , 2007, The Journal of Immunology.

[61]  Adrian G Barnett,et al.  Regression to the mean: what it is and how to deal with it. , 2004, International journal of epidemiology.

[62]  A. Kehlen,et al.  Expression, modulation and signalling of IL‐17 receptor in fibroblast‐like synoviocytes of patients with rheumatoid arthritis , 2002, Clinical and experimental immunology.

[63]  R. Kelley,et al.  IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding , 2001, The EMBO journal.